Trial · NCT07549594
Prophylaxis of Recurrent Erysipelas in Lower Limbs: compreSsion thErapy vs aNTibiotics and Compression Therapy.
NCT07549594, Phase 4, Not yet recruiting, University Hospital, Tours
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Prophylaxis of Recurrent Erysipelas in Lower Limbs: compreSsion thErapy vs aNTibiotics and Compression Therapy. Trials, record NCT07549594. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07549594
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Prophylaxis of Recurrent Erysipelas in Lower Limbs: compreSsion thErapy vs aNTibiotics and Compression Therapy.
- NCT number
- NCT07549594
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 200 participants, estimated
- Lead sponsor
- University Hospital, Tours
- Conditions
- Recurrent Erysipelas
- Interventions
- elastic stockings, Phenoxymethylpenicillin
- First posted
- 2026-04-24
- Last updated
- 2026-04-24
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients with at least one recurrence of erysipelas during the 1-year prophylaxis phase, performed by a assessor-blinded | From enrollment to the end of treatment at 12 months | Proportion of patients with at least one recurrence of erysipelas during the 1-year prophylaxis phase, performed by a assessor-blinded Diagnosis will be done by a blinded evaluator (investigator) different from those who recruited the patients, in the following 48h after the first sign of recurrence (fever, chills and/or erythematous plaque). Recurrence of erysipelas will be diagnosed as sudden onset (\<24h) of a well demarcated cutaneous inflammation (redness, warmth, edema and pain), with fever (\>38°C) and/or chills |
| Secondary | Time to the first confirmed recurrence of erysipelas | From enrollment to the first confirmed recurrence of erysipelas, e.g.up to 52 weeks | |
| Secondary | Severity of recurrence : erysipelas-related hospital admission (number of nights in hospital for cellulitis) | From enrollment to the end of treatment at 12 months | Erysipelas-related hospital admission : number of nights in hospital for cellulitis because treatment of erysipelas is normally an outpatient treatment, hospital admission is considered as a marker of severity of erysipelas. |
| Secondary | Severity of recurrence: presence of skin necrosis or ulceration | From enrollment to the end of treatment at 12 months | |
| Secondary | Assessment of adverse effects and serious adverse effects during the study | From enrollment to the end of treatment at 12 months | |
| Secondary | Quality of life: Dermatology Life Quality Index (DLQI) | Month 0, Month 3, Month 6, Month 9, Month 12 and in case of potential recurrence, e.g.up to 52 weeks | Stantardized questionnaire with minimum value = 0 (better out come) and maximum value = 30 (worse outcome) |
| Secondary | Quality of life: EuroQuol-5 Dimensions-5 Levels standardised questionnaire (EQ-5D-5L) | Month 0, Month 3, Month 6, Month 9, Month12 and in case of potential recurrence | EQ-5D-5L (EuroQuol 5 Dimensions 5 Levels standardised questionnaire) was introduced by the EuroQol Group in 2009 to improve the instrument's sensitivity and to reduce ceiling effects. |
| Secondary | Adherence: number of days per week that compression was worn | From enrollment to the end of treatment at 12 months | Using a patient diary. Patients' adherence with compression therapy, which is known to be low |
| Secondary | Adherence: assessment of oedema by circumferential measurements | Month 0, Month 6, Month 12 | By evaluator (assessor-blinded during the follow-up) and devoted tool (excel calculator) will be built accordingly to give automatically the truncated cone formula |
| Secondary | Adherence: number of days per week that antibiotics is taken | From enrollment to the end of treatment at 12 months | Using a patient diary |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07549594
GET https://conductscience.org/api/trials/v1/NCT07549594/registered